老虎证券

BRIEF-Bristol Myers Squibb Receives European Commission Approval For Perioperative Regimen Of Neoadjuvant Opdivo(Nivolumab) And Chemotherapy Followed By Adjuvant Opdivo For Resectable, High-Risk Non-Small Cell Lung Cancer With Pd-L1 Expression ≥1%

Reuters
2025/05/16
BRIEF-Bristol Myers Squibb Receives European Commission Approval For Perioperative Regimen Of Neoadjuvant Opdivo(Nivolumab) And Chemotherapy Followed By Adjuvant Opdivo For Resectable, High-Risk Non-Small Cell Lung Cancer With Pd-L1 Expression ≥1%

May 16 (Reuters) - Bristol-Myers Squibb Co BMY.N:

  • BRISTOL MYERS SQUIBB RECEIVES EUROPEAN COMMISSION APPROVAL FOR PERIOPERATIVE REGIMEN OF NEOADJUVANT OPDIVO® (NIVOLUMAB) AND CHEMOTHERAPY FOLLOWED BY ADJUVANT OPDIVO FOR RESECTABLE, HIGH-RISK NON-SMALL CELL LUNG CANCER WITH PD-L1 EXPRESSION ≥1%

Source text: ID:nBw8StG8ha

Further company coverage: BMY.N

((Reuters.Briefs@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10